Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Pratish C Patel"'
Autor:
Guohua An, C. Buddy Creech, Nan Wu, Roger L. Nation, Kenan Gu, Demet Nalbant, Natalia Jimenez-Truque, William Fissell, Stephanie Rolsma, Pratish C. Patel, Amy Watanabe, Nicholas Fishbane, Carl M. J. Kirkpatrick, Cornelia B. Landersdorfer, Patricia Winokur
Publikováno v:
Antimicrobial Agents and Chemotherapy. 67
In the present study, population pharmacokinetic (PK) analysis was performed based on meropenem data from a prospective study conducted in 114 critically ill patients with a wide range of renal functions and various disease conditions. The final mode
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1a09f26aad082cff9a93bf435d390a17
https://doi.org/10.1128/aac.01312-22
https://doi.org/10.1128/aac.01312-22
Autor:
Stephanie L Rolsma, Guohua An, Nick Fishbane, William Fissell, Kenan Gu, Natalia Jimenez, Carl Kirkpatrick, Cornelia B Landersdorfer, Roger L Nation, Pratish C Patel, Andrew G Sokolow, Katherine Sokolow, Mary E Teresi, Marissa Kontos, Amy Watanabe, Patricia Winokur, C Buddy Creech
Publikováno v:
Open Forum Infectious Diseases. 9
Background Patients with cystic fibrosis (CF) experience recurrent bacterial pulmonary exacerbations. The management of these infections becomes increasingly complex due to decreased antimicrobial susceptibility and inadequate pharmacokinetic/pharmac
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4637d5693edcdac4cfae3f8bb8ac2ec1
https://doi.org/10.1093/ofid/ofac492.649
https://doi.org/10.1093/ofid/ofac492.649
Publikováno v:
Open Forum Infectious Diseases
Background Approximately 10% of the population is labeled as penicillin (PCN) allergic, while only 1% of these individuals have a true IgE mediated allergy. This label influences the prescription of the most appropriate antibiotic and ultimately lead
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::088eaa4cce870d0e493032350a55cce0
http://europepmc.org/articles/PMC8644258
http://europepmc.org/articles/PMC8644258
Publikováno v:
Open Forum Infectious Diseases
Background In the setting of the global pandemic due to COVID-19, high-risk patients with mild to moderate disease were identified as a group who would benefit from COVID-19 monoclonal antibody (mAB) treatment to mitigate progression to severe diseas
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::09ae96181ba6c5448fdc77e8f609d942
https://doi.org/10.1093/ofid/ofab466.736
https://doi.org/10.1093/ofid/ofab466.736